

## **Annual General Meeting of Q-Med AB (publ)**

The Board of Directors of Q-Med AB (publ) has of today published a notice to attend the Annual General Meeting, which will be held on Thursday May 3 at 3 p.m. on Q-Med's new premises. Entrance from Fyrisvallsgatan 5, Uppsala, Sweden. A notice has been published in Upsala Nya Tidning, Svenska Dagbladet and in Post- och Inrikes Tidningar (Swedish Official Gazette). The complete notice of the Annual General Meeting in English can be found on the corporate web site [www.q-med.com](http://www.q-med.com), and is also attached.

### **Q-Med AB (publ)**

The Board

#### **Queries should be addressed to:**

Madelene Sandgren, Director Investor Relations and Corporate Communications,  
Tel: + 46 (0) 70-974 90 15

---

*Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA™ for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: RESTYLANE for the filling out of lips and facial wrinkles and for facial contouring, DUROLANE, for the treatment of osteoarthritis of the hip and knee joints, DEFLUX for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, ZUIDEX, for the treatment of stress urinary incontinence in women and SOLESTA, for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 600 co-workers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Large Cap segment of the OMX Nordic Stock Exchange in Stockholm.*

*NASHA, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product names within the RESTYLANE family are trademarks that belong to Q-Med AB.*

---

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.  
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: [info@q-med.com](mailto:info@q-med.com). Web: [www.q-med.com](http://www.q-med.com).

**In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.**